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DPP4 in diabetes
Diana Röhrborn, Nina Wronkowitz and Juergen Eckel*
Paul-Langerhans-Group for Integrative Physiology, German Diabetes Center, Düsseldorf, Germany
Dipeptidyl-peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously
expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-
terminal dipeptides from a variety of substrates, including cytokines, growth factors, neu-
ropeptides, and the incretin hormones. Expression of DPP4 is substantially dysregulated
in a variety of disease states including inflammation, cancer, obesity, and diabetes. Since
the incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic
polypeptide (GIP), are major regulators of post-prandial insulin secretion, inhibition of
DPP4 by the gliptin family of drugs has gained considerable interest for the therapy of
type 2 diabetic patients. In this review, we summarize the current knowledge on the
DPP4–incretin axis and evaluate most recent findings on DPP4 inhibitors. Furthermore,
DPP4 as a type II transmembrane protein is also known to be cleaved from the cell
membrane involving different metalloproteases in a cell-type-specific manner. Circulating,
soluble DPP4 has been identified as a new adipokine, which exerts both para- and
endocrine effects. Recently, a novel receptor for soluble DPP4 has been identified, and
data are accumulating that the adipokine-related effects of DPP4 may play an important
role in the pathogenesis of cardiovascular disease. Importantly, circulating DPP4 is
augmented in obese and type 2 diabetic subjects, and it may represent a molecular
link between obesity and vascular dysfunction. A critical evaluation of the impact of
circulating DPP4 is presented, and the potential role of DPP4 inhibition at this level is also
discussed.
Keywords: CD26/DPP4, soluble DPP4, type 2 diabetes mellitus, incretins, DPP4 inhibitors/gliptins, multifunctional
enzyme
Introduction
Dipeptidyl-peptidase (DPP) 4, which is also known as CD26, is a ubiquitously expressed glycopro-
tein of 110 kDa, which was first characterized by Hopsu-Havu and Glenner (1). DPP4 is a type II
transmembrane protein, which is also cleaved off the membrane and released into the circulation by
a process called shedding (2, 3). The importance of DPP4 for the scientific and medical community
raised substantially since the approval ofDPP4 inhibitors for the treatment of type 2 diabetesmellitus
(T2DM). These so-called gliptins increase the incretin levels and therefore prolong the post-prandial
insulin action. Since soluble DPP4 is characterized as an adipokine (4) and also correlates with
parameters of themetabolic syndrome (5), itmight also be an importantmolecular biomarker. DPP4
is amultifunctional enzyme, which serves as a binding partner for numerous peptides, amongwhich
are adenosine deaminase (ADA) and extracellular matrix proteins (2, 6, 7). Moreover, as a serine
protease, DPP4 cleaves numerous substrates, which further amplifies its complexity of action. Thus,
DPP4 is involved in signaling processes, immune cell activation, and its dysregulated expression and
release is associated with numerous diseases.
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In the present review, we wanted to emphasize the complex
function of DPP4 with special focus on its association to T2DM.
Furthermore, we wanted to offer a different perspective of the
current view of DPP4 beyond the inhibition of its protease activity
(8–10). The first part of the present review is dealing with general
information about DPP4 and its numerous biological functions
in regard to T2DM and its treatment. The last section collects
the current knowledge about how DPP4 with its pleiotropic func-
tions, as described before, affects several organs, thereby playing a
pivotal role in the development of T2DM and its comorbidities.
General Information on DPP4
Biology of DPP4
The following part will deal with the domain architecture
and respective relevance of these domains for the functionality
of DPP4.
Dipeptidyl-peptidase 4 (EC3.4.14.5) is a type II transmembrane
protein, which groups together with fibroblast-activation protein
α (FAP), the resident cytoplasmic proteins, DPP8 and DPP9, and
the non-enzymatic members, DPP6 and DPP10, to the serine
peptidase subfamily S9B. All of these proteins share a typical
α/β hydrolase fold (2, 6). The DPP4 protein consists mainly of
4 domains: a short cytoplasmic domain (1–6), a transmembrane
domain (TMD) (7–28), a flexible stalk segment (29–39), and the
extracellular domain (40–766), which can be further separated
by a highly glycosylated region, the cysteine-rich region, and the
catalytic region (Figure 1).
As a member of the type II transmembrane proteins, DPP4
contains a typical signal peptide, which is necessary for the
targeting to the endoplasmatic reticulum and the initiation of
the translocation across the cell membrane. In contrast to the
classically secreted proteins, the signal peptide is not cleaved off,
but serves as a membrane anchor. We were able to show that the
circulating form of DPP4 (sDPP4), which lacks the cytoplasmic
domain and the transmembrane region, is cleaved off the mem-
brane of human adipocytes and smooth muscle cells in a process
called shedding by the involvement of matrix metalloproteases
(MMPs) (3).
Within the TMD, it could be shown that proline residues play
an important role for the translocation of membrane-anchored
proteins, such as DPP4. Chung and colleagues (11) studied sin-
gle proline substitution throughout the TMD of DPP4. They
were able to show that translocation and integration into the
membrane are determined by the hydrophobicity, conforma-
tion, and also the location of proline within the TMD. Further-
more, the position of proline relative to other prolines and the
location of highly hydrophobic residues within the TMD are
important for correct translocation and membrane integration
of DPP4.
In addition to the TMD, the glycosylation of DPP4 is also
important for the correct trafficking of DPP4. Carbohydrates
account for approximately 20% of the total molecular mass of
DPP4 and cause heterogeneity of this protein depending on the
location on different cell types. Two highly conserved gluta-
mate residues (205 and 206) within the glycosylated region are
essential for the activity of DPP4 (12). Interestingly, six of the
nine N-glycosylation sites are located within the glycosylated
region. These glycosylation sites are mostly conserved among
species. They are necessary for folding, stability, and intracellu-
lar trafficking (13). Other modifications like sialylation and/or
O-glycosylation have an impact on targeting DPP4 to the cell
membrane. Sialyation of DPP4 increases significantly with age,
and hypersialyation occurs in patients with HIV infection (14).
FIGURE 1 | Domain structure of DPP4 [adapted from Ref. (2)].
Schematic representation of the membrane-bound DPP4 monomer. The
extent of the circulating and soluble form of DPP4 is illustrated on the left
in blue. The shedding of DPP4 from the membrane by indicated matrix
metalloproteinases is shown by a scissor symbol in red. The vertical black
bar on the right represents the primary structure with the delineation of
the different regions. In green are interactions collected, which occur in
the indicated region of the DPP4 structure. MMP, matrix
metalloproteinase; M6P/IGFII, mannose-6 phosphate/insulin-like growth
factor 2.
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Not only glycosylation and residues within the TMDare impor-
tant for the cellular function of DPP4 but also dimerization.
DPP4 can be found as monomer, homodimer, or even as homote-
tramer on the cell surface of cells. DPP4 needs dimerization for
enzymatic activity, and this is the predominant form of DPP4
(15). Dimerization occurs upon interaction with DPP4 itself or
with other binding partners, e.g., FAP (16, 17), and occurs via
interaction with the cysteine-rich region. Through its interaction
with several proteins, DPP4 can act also in an enzymatic activity-
independent way. Through this interaction, DPP4 is linked to
various mechanisms like immune response and tumor invasion.
The heterodimerization and interaction with different binding
partners will be discussed in a later section.
The serine in the active site of DPP4 is located in the sequence
Gly–Trp–Ser–Tyr–Gly and is part of the catalytic triad (Ser 630,
Asp 708, His 740) within the catalytic region of DPP4. DPP4 is an
exopeptidase, which cleaves dipeptides from the penultimate N-
terminal position of its substrates and thereby either inactivates
these peptides and/or generates new bioactive compounds (7).
There are numerous different DPP4 substrates known to date and
they will be addressed in a separate section within this review.
DPP4 Expression and Its Regulation
Dipeptidyl-peptidase 4 is ubiquitously expressed on numerous
different cell types among which are epithelial cells, fibroblasts,
and leukocyte subsets. Mechanisms that regulate DPP4 gene tran-
scription and enzymatic activity are not fully understood so far
and may be dependent on the studied cell type.
The human DPP4 gene is located on chromosome 2, spans
70 kb, and consists of 26 exons (2). The DPP4 promoter region
contains consensus sites for different transcription factors like
NFκB, SP-1, EGFR, and AP-1 factor NF-1 (18). At least in chronic
b lymphocytic leukemia cells, it could be shown that there is
a consensus interferon γ-activated sequence (GAS), which is a
binding motif for STAT1. The interferons, α, β, and γ, stimulate
STAT1α binding to this region and thus lead to an increasedDPP4
expression and activity (19). Interleukin (IL) 12, which is a key
factor in differentiation of naïve T-cells into the Th1 subtype,
is also able to upregulate DPP4 expression. Therefore, DPP4 is
important in immune cell activation (20, 21). Our group was able
to show that release of soluble DPP4 is increased upon TNFα
stimulation and insulin in vitro (4). However, IL-12 and TNFα
also seem to play a regulatory role in translation and translocation
of DPP4. In activated lymphocytes, IL-12 upregulates DPP4 trans-
lation whereas TNFα decreases cell surface expression, which
might be due to elevated sDPP4 release (22). Also transcription
factors, such as HIF-1α and HNFs, target DPP4 expression (23),
which fits to the observation of our group that hypoxia induces
DPP4 release in human smooth muscle cells, which might be
mediated by MMPs (3).
Non-Enzymatic Interactions of DPP4
Through its cysteine-rich region, which is separated from the
catalytic region, DPP4 is able to interact with different proteins,
and further broadens its spectrum of activity and highlights its
multifunctional role in different processes.
Binding Partners of Membrane-Bound DPP4
The best-studied interaction in this regard is certainly the binding
of DPP4 and ADA. It was already identified in 1993 by Morrison
and colleagues (24). Importantly, the interaction of DPP4 and
ADA preserves the enzymatic function of both binding partners.
It has been shown that residues 340–343 of DPP4 are essential for
the interaction with ADA. Regulation of the DPP4/ADA inter-
action occurs, e.g., via tetramerization of DPP4 or glycosylation
at Asn281, which interferes with ADA binding (25). Also, the
HIV envelope glycoprotein, gp120, which interacts with DPP4 on
lymphocytes via its C3 region, is able to inhibit the association
with ADA (2). Upon ADA binding, activation of plasminogen-2
occurs, which raises plasmin levels. This leads to a degradation
of matrix proteins and an activation of MMP, thereby indicating
that the interaction of DPP4 and ADAmight be involved in tissue
remodeling (26).
Furthermore, ADA catalyzes the irreversible deamination of
adenosine and 20-deoxyadenosine and is therefore a crucial player
in the cellular and humoral immunity. Via interaction with CD45,
the complex of ADA and DPP4 enhances T-cell activation. Inter-
estingly, DPP4 is also able to promote T-cell proliferation inde-
pendent from ADA binding or even its enzymatic activity (27).
Zhong et al. were able to show that the interaction of DPP4 and
ADA on dendritic cells might potentiate inflammation in obe-
sity upon activation and proliferation of T-cells, which could be
competitively inhibited by exogenous sDPP4, but not by inhibit-
ing DPP4 enzymatic function (28). Furthermore, ADA activity
is elevated in T2DM patients and may serve as a marker of
inflammation and obesity (29).
Beside its role in inflammation, adenosine is also an important
player in glucose homeostasis. Already in 1988 it was shown
that, by lowering endogenous adenosine levels, ADA contributes
to a reduced insulin sensitivity of glucose transport stimulation
(30). Additionally, adenosine seems to facilitate insulin action
in adipocytes (31). Another study could show a correlation of
increased ADA activity in T2DM with fasting plasma glucose,
HbA1c, aspartate, and alanine aminotransferase (ALT). DPP4
inhibitors exert no additional effects on ADA activity despite
glycemic control or HbA1c-dependent effects (32). All these
studies emphasize that the effects of ADA/DPP4-interaction are
independent of DPP4 enzymatic activity.
Another known interaction partner of DPP4 is Caveolin-1,
which is present on antigen-presenting cells (APCs) and binds to
residues 630 and 201–211 of DPP4 expressed on T-cells. Thereby,
an upregulation of CD68 occurs and initiates a signaling cas-
cade, which might be implicated in the pathogenesis of arthritis,
and may be relevant for other inflammatory diseases as well
(33). Intracellular signaling is also initiated by DPP4 via inter-
action with Caspase recruitment domain containing protein 11
(CARMA-1) (6).
Another well-known interaction of DPP4 is with extracellular
matrix proteins like collagen and fibronectin (34, 35). The inter-
action of DPP4 with fibronectin was revealed via nitrocellulose
binding assays in rat hepatocytes and seems to play a role in the
interaction of these cells with the ECM and with matrix assembly
(36). Interaction of DPP4 with FAPα leads to a local degradation
of ECM and thus migration and invasion of endothelial cells (37).
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Potential Receptors for sDPP4
Since DPP4 is shedded from the membrane of cells with intact
enzymatic and cysteine-rich region, it can also exert biological
functions in a paracrine or endocrine manner. These functions
might also involve intracellular signaling events in the targeted
cells. Therefore, it would be of great importance to know receptors
of sDPP4 to better understand the multiple role of sDPP4 on
different cells and in different disease conditions where serum
levels are elevated.However, there is notmuch known aboutDPP4
receptors so far.
Ikushima et al. were able to show that DPP4 needs to associate
with mannose-6 phosphate/IGF-IIR to exhibit its function as T-
cell activator. This is due to the fact that for this activation,
internalization of DPP4 is necessary, but DPP4 lacks a signal
for exocytosis. The binding with M6P/IGF-IIR occurs via M6P
residues in the carbohydrate moiety of DPP4 and the complex is
then internalized and able to exert its biological function (38).
Our group showed that at least in human vascular smoothmus-
cle cells, protease-activated receptor 2 (PAR2) might be activated
by sDPP4. We were able to show that sDPP4-mediated ERK acti-
vation and proliferation, as well as upregulation of inflammatory
cytokines could be prevented by silencing of PAR2. The same
was shown by use of a specific PAR2 antagonist. We propose
that sDPP4 acts as an activator of PAR2, since a sequence within
the cysteine-rich region of DPP4 is highly homologous to the
auto-activating tethered ligand of PAR2 (39).
Genetic Alterations of DPP4 and Predisposition
to T2DM-Associated Diseases
There are only few studies aiming to identify modifications in the
DPP4 gene and their association with T2DM. Some of these are
reviewed in the following section.
In 2009, Bouchard et al. analyzed single nucleotide polymor-
phisms (SNPs) in the DPP4 gene and searched for association
with blood pressure, lipids, and diabetes-related phenotypes in
obese individuals, to verify whether DPP4 gene polymorphisms
could explain the individual risks of obese patients to develop
metabolic complications. Three of the analyzed SNPs showed sig-
nificant association with plasma total-cholesterol levels or plasma
triglyceride level or total cholesterol level. But none of the poly-
morphisms or cardiovascular disease risk factors showed a sig-
nificant correlation with DPP4 mRNA levels in omental adipose
tissue. Therefore, the authors concluded that, at least in their
studied group, DPP4 gene polymorphisms seem to be unrelated to
the inter-individual risk of developing obesity-related metabolic
complications (40).
In another study, visceral adipose tissue DNA of 92 severely
obese, non-diabetic female patients was analyzed for methylation
rate in the DPP4-promoter CpG island and compared between
differentDPP4 polymorphisms. These cytosine- and guanine-rich
regions are prone to epigenetic modification like methylation,
and thus inactivate or activate transcription of certain genes.
Different methylation levels of the DPP4 gene were identified in
three DPP4 SNPs. Interestingly, the methylation level was nega-
tively associatedwithDPP4mRNAabundance and positively with
plasma total/HDL-cholesterol ratio. These observations suggest
that plasma lipid profile is improved by a higher methylation
status of the investigated CpGs (41). Two years later, the same
group analyzed DPP4 gene methylation levels between obese sub-
jects with and without themetabolic syndrome in visceral adipose
tissue. They observed no significant difference in the percentage
of methylation levels of the CpGs within or near the second exon
of the DPP4 gene between non-diabetic severely obese subjects
with or without metabolic syndrome. However, they were able
to show a correlation between plasma cholesterol levels and the
percentage of methylation when the subjects were classified into
quartiles (42). This further underpins a link between epigenetic
modification of the DPP4 gene and plasma lipid metabolism.
Aghili et al. analyzed 875 patients with angiographically docu-
mented coronary artery disease (CAD), and divided them in two
subgroups dependent of their myocardial infarction (MI) status.
By a genome-wide association study, loci, which predispose to
MI, were assessed and associated with SNPs in the DPP4 gene.
They found that polymorphisms in the DPP4 gene increase the
risk of MI and progression of atherosclerosis in terms of plaque
stability in patients with already existing CAD. Especially, one
SNP was identified in both dominant and additive inheritance
modes, which associates with low plasma DPP4 levels and which
may increase the risk of MI in CAD patients (43).
Dyslipidemia, which is characterized by excessive lipids in the
blood, is a common feature of T2DM. The status of this risk factor
is quantifiable by the measurement of apolipoprotein B (ApoB)
in the blood. In a very recent study by Baileys and colleagues,
they aimed to identify novel SNPs associated with ApoB level.
Especially in South Asians, who tend to develop risk factors for
T2DM and MI at younger ages and lower BMI, they found an
association of a DPP4 SNP with ApoB level (44).
The DPP4 Deficiency in Animal Models
To date, there are several studies dealing with the question, which
role DPP4 plays in vivo. Animal models are useful tools to study
the involvement of DPP4 in different organs. Upon triggering
different diseases like insulin resistance (IR) or MI, it is possible
to understand the role of DPP4 in these comorbidities of T2DM.
DPP4 Deficiency in Rats
A major part of the literature is dealing rather with DPP4-KO in
rats than inmice.Most research groupsworkwith the F344/DuCrj
(DPP4-deficient) strain. Rats developing IR due to high-fat diet
(HFD) feeding showed improved HOMA-IR values and blood
glucose levels in oral glucose tolerance test (oGTT) and more
active glucagon-like peptide-1 (GLP-1) and insulin in plasma
(45). The same improved glucose tolerance with increased GLP-
1 and leptin levels was found in DPP4-depleted Dark Agouti
rats with diet-induced obesity (46). Another research group also
found improvement in serum lipid profile despite increased vis-
ceral fat. They also performed insulin tolerance tests (ITT) in
addition to GTT and saw an increased phosphorylation of Akt
and reduced expression of gluconeogenic genes, concluding that
DPP4-KO improved insulin sensitivity. Furthermore, the KO rats
showed increased adipocyte maturation by increased expression
of genes involved in triglyceride uptake and in PPARγ expression
and increased adiponectin and leptin levels. In addition, adipose
tissue is less inflamed illustrated by lower TNFα, IL-6, PAI1, and
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CCL7 levels (47). The observed effects were attributed to elevated
glucose-dependent insulinotropic polypeptide (GIP) levels in the
KO rats. Furthermore, the same group could also show attenuated
liver damage underHFD challenge in the KO rats due to improved
bile secretory function. They postulate that the enhanced export
of bile acids out of hepatocytes and a reduction of bile acid
synthesis via inhibition of CYP7A1, which converts cholesterol
to bile acids, were mediated by increased GLP-1 in DPP4-KO
rats (48). Interestingly, at least Yasuda and colleagues also saw
a significant reduced food intake in the KO rats irrespective of
the diet (45), which might be due to changed receptor specificity
of neuropeptide Y (NPY), which was shown to be more potent
in KO rats to influence food intake and feeding motivation (49).
Although several independentworking groups saw increasedNPY
levels in KO rats (49–51), the effect on food intake is controver-
sial (45, 50). When diabetes is induced via streptozotocin (STZ)
treatment in F344/DuCrj-DPP4-deficient rats, onset of hyper-
glycemia was delayed, but KO rats showed impaired creatinine
clearance andmore severe dyslipidemia, whichmight be caused by
a dysregulated expression of factors involved in steroid and lipid
metabolism (52, 53). The authors concluded that DPP4 might be
responsible for preservation of renal function. Another effect of
the whole-body KO of DPP4 in rats is induction of behavioral
changes like a blunted stress phenotype (46, 51) and also effects
on the immune-regulatory system like blunted NK cell and T-cell
function and differential leukocyte subset composition or altered
cytokine levels (46, 47).
DPP4 Deficiency in Mice
Most of the observations already described in deficient rats are
also true in whole-body DPP4-KO mice. Marguet et al. showed
enhanced glucose tolerance, lower plasma glucose, and higher
plasma insulin andGLP-1 after a 15min oral glucose load without
further characterizing the diet, age, or sex of the used C57BL/6
DPP4-KOmice (54). Conarello and colleagues found less weight-
gain independent of the diet, and marked hypertrophy in the
HFD-fed KO mice in epididymal white (eWAT) and brown adi-
pose tissue (BAT). Importantly, they admitted that the reduction
in caloric intake accounted for ~70% of the observed changes
in bodyweight. Although they still observed differences in the
bodyweight between KO and WT when they used pair-feeding,
they carried out their further analysis in ad libitum fed mice and
it is therefore difficult to judge the influence of DPP4 irrespective
of bodyweight. However, they found improved insulin sensitivity
and islet morphology, and improved liver biology in respect to
lipid content and marker gene expression (55). The observation
that DPP4 might be involved in the immune-regulatory system
was also investigated in DPP4-KO mice, which were treated with
pokeweed mitogen that stimulates growth and proliferation of B-
cells. DPP4 seems to be involved in maturation and migration
of immune cells, cytokine secretion, and percentages of spleen
lymphocytes (56).
All these studies have in common that they use whole-body
KO animals. The disadvantage here is that one cannot distinguish
between direct effects of the KO and side effects caused, for exam-
ple, by different immune cell status or decreased caloric intake.
To really decipher the role of DPP4 in different tissues and their
crosstalk with other target tissues, it is of great importance to study
tissue-specific KO models.
Because of this and because we were the first to describe DPP4
as a novel adipokine linked to parameters of the metabolic syn-
drome (4), we decided to develop an adipose tissue-specific KO
mouse model. The AT-specific DPP4-KO mouse was generated
using a Cre-lox strategy under control of the aP2 promoter on
the C57BL/6J background. Interestingly, we found out that KO
mice gained significantly more weight, fat, and lean mass under
HFD with no effect on energy expenditure or food intake. How-
ever, KO mice showed improved HOMA-IR and lower fasting
insulin. The observations that within AT, KO mice display a shift
toward significantly more smaller adipocytes, and an increased
expression of M2 macrophage marker genes points toward a ben-
eficial role of DPP4 deletion in adipose tissue remodeling during
HFD (57, 58).
Enzymatic Function of DPP4
Dipeptidyl-peptidase 4 exerts its enzymatic action by clipping
dipeptides from the penultimate position of its substrates. The
active center, which is housed in an internal cavity, is surrounded
by the β-propeller domain and the catalytic domain. Inhibitors
and substrates enter/leave the active center by a so-called “side
opening” (59, 60). The following section deals with known sub-
strates of DPP4 in respect of T2DM, and with DPP4 as a drug
target for T2DM treatment, which will include current knowledge
on DPP4 inhibitors and the impact of DPP4 on organs involved in
complications of T2DM.
DPP4 Substrates
In theory, numerous peptides are potential DPP4 substrates since
they contain the cleavable amino acid sequence at their penul-
timate position, but not for all of them it could be shown that
DPP4 is able to cleave them in vivo. There seems to be a size
limitation at least for cytokines, where DPP4 is more prone to
cleave substrates of around 24 amino acids (aa) length. Fur-
thermore, the substrate recognition is also dependent on the aa
sequence around the penultimate position (61, 62). It turned
out to be difficult to find physiological targets of DPP4 in the
literature, reasons of that are excellently summarized in a recent
review by Mulvihill and Drucker (6). We decided to focus here
on the (potential) substrates of DPP4, which might play a role
in T2DM or its complications. The list of DPP4 substrates men-
tioned here is not fully complete and aims to highlight the impor-
tance of DPP4 in T2DM also beyond its well-known incretin
effect.
Incretin Hormones
The incretin hormones account for approximately 50% of the
insulin secretion after meal intake and are secreted from the gut
within minutes after the meal intake. Through binding to distinct
receptors on beta cells in the pancreas, they stimulate insulin
secretion and suppress glucagon release depending on the blood
glucose level. Most potent in their glucose-lowering action are
glucagon-like peptide 1 (GLP-1) and GIP. Both peptides belong
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to the same glucagon peptide superfamily and share significant aa
character.
Glucagon-like peptide-1 is secreted from L-cells of the gut
into the bloodstream. Upon binding to G-protein-coupled recep-
tors on the beta cells, intracellular cAMP level is elevated and
the protein kinases, Epac1 and 2, are activated, which leads to
an increase of insulin secretion. Furthermore, GLP-1 enhances
beta-cell mass by mediating proliferation and differentiation and
inhibiting apoptosis (8). By inhibiting gastric emptying, GLP-1
also improves blood sugar excursion, delays food absorption, and
is therefore a regulator of satiety and appetite also through the
hypothalamus (63).
Glucose-dependent insulinotropic polypeptide is a 42 aa pep-
tide, which mainly originates from enteroendocrine K cells (64).
Subjects with diabetes or impaired glucose tolerance show sig-
nificantly reduced levels of meal-stimulated circulating GIP and
the levels are negatively correlated with the severity of IR in
the patients (65, 66). GIP has, in contrast to GLP-1, no effect
on glucagon secretion, but also regulates fat metabolism in
adipocytes (67).
Since inhibition of DPP4 due to genetic deletion or use of DPP4
inhibitors was shown to elevate GLP-1/GIP levels in numerous
studies, this effect is the main focus of developing therapeutic
targets for treatment of T2DM. There are numerous reviews,
which focus on DPP4- and GLP-1-mediated effects, and this topic
will not be further discussed here.
Stromal Cell-Derived Factor-1α/CXCL12
Stromal cell-derived factor-1 (SDF-1) is a chemokine that pro-
motes angiogenesis and attracts endothelial progenitor cells (EPC)
by binding to its receptor C–X–C motif chemokine receptor type
4 (CXCR4). SDF-1 is thus discussed in the literature as important
mediator of cardioprotective effects addressed to the use of DPP4
inhibitors (further discussed in “DPP4 Substrates: SDF-1- and
BNP-Dependent Effects of DPP4 Inhibitors”). It is a well-known
physiological target of DPP4 (68, 69). SDF-1α also plays a role in
diabetes itself by protecting stem-cell-derived insulin-producing
cells from glucotoxicity under high glucose conditions (70) or
promoting pancreatic beta-cell survival in mice via Akt activation
(71). Furthermore, it was shown that some genetic variants of
SDF-1α are associated with late stage complications in T2DM
patients (72, 73).
NPY and PYY
Neuropeptide Y and peptide YY are members of the polypeptide
family. They are highly expressed in the hypothalamus but are also
present in peripheral tissues like islets. NPY regulates energy bal-
ance, memory, and learning, while PYY reduces appetite, inhibits
gastric motility, and increases water and electrolyte absorption
in the colon (74). Both NPY and PYY play a role in beta-
cell survival and in glucose homeostasis (74). NPY is able to
suppress insulin secretion acutely (75). Both polypeptides have
in common that DPP4 truncation shifts their receptor speci-
ficity and thus alters their biological role in different cellular
processes. In vitro experiments in adipocytes could show that
DPP4 inhibition has an impact on lipid metabolism mediated by
NPY (76, 77).
Substance P
Substance P is a physiological target ofDPP4, which is sequentially
converted to SP (3–11) and SP (5–11) in vivo in F344–DPP4-
positive rats (78). SP is a neurotransmitter and modulator, which
is involved in neurogenic inflammation. Serum levels in diabetes
are controversially discussed with one study showing a decrease
in diabetic patients (79), and another one showing an increase in
fasting blood samples with correlation to diabetic risk factors like
BMI and blood pressure (80). This discrepancy in serum levels
could be addressed to the fact that it is not always stated which
form of SP (full length versus truncated) is measured. However,
SP was shown to promote IR in vitro in human preadipocytes
by interacting with proteins that are involved in the inhibitory
phosphorylation of IRS-1. Furthermore, SP can directly inhibit
insulin-dependent glucose metabolism in rat adipocytes (81). SP
also promotes diabetic corneal wound healing, as shown by Yang
and colleagues (82).
Brain Natriuretic Peptide
Brain natriuretic peptide is responsible for vasodilation, natriure-
sis, and suppresses renin secretion. It is so far only a predicted
DPP4 substrate, which was cleaved in vitro by DPP4 to BNP
(3–32). This truncation was inhibited by a DPP4 inhibitor in a
dose-dependentmanner (83). Truncated forms of BNPwith lower
enzymatic activity are discussed as an indicator of heart failure
severity. In 2013, dos Santos et al. could show an improved cardiac
performance in sitagliptin-treated rats, which they attributed to
increased levels of active BNP (84).
Pituitary Adenylate Cyclase-Activating Polypeptide
Pituitary adenylate cyclase-activating polypeptide (PACAP) is
very rapidly degraded by DPP4 to the fragments (3–27), (5–27),
and (6–27). These fragments lack PACAPs insulinotropic ability,
but are no feasible treatment options for T2DM because of their
actions on glucose homeostasis and glucagon secretion (85). Sev-
eral studies have shown that PACAP is a powerful stimulator of
insulin secretion, which enhances glucose uptake in adipocytes
and augments antilipolytic action of insulin (86, 87). After DPP4-
inhibitor treatment in mice, PACAP-induced insulin secretion
was enhanced (88). However, a proof that PACAP also plays a role
in humans is lacking so far.
Regulated on Activation, Normal T-Cell Expressed
and Secreted/CCL5
Regulated on activation, normal T-cell expressed and secreted
(RANTES) recruits leukocytes into inflammatory sites and is
cleaved by DPP4 to RANTES (3–68). Due to this truncation,
RANTES (3–68) is not able anymore to increase cytosolic calcium
concentrations and to induce chemotaxis of human monocytes
in vitro. This is explained by a shift in receptor subtype-specificity
toward enhanced activation of CC-motif-chemokin-receptor 5
(CCR5) (89). Elevated serum levels of RANTES in T2DM are
associated with post-prandial hyperglycemia (90). Interestingly,
RANTES and its receptor CCR5 are important mediators of
obesity-induced inflammation, which was shown in CCR5-KO
mice (91). Levels of RANTES and CCR5 were reduced in adipose
tissue of obese patients upon exercise (92). RANTES reduces
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glucose-stimulated GLP-1 secretion in vitro and in vivo in mice,
by actingmost probably through the intestinal glucose transporter
SGLT1 (93).
Eotaxin/CCL11
Eotaxin mediates mobilization of eosinophils into the blood-
stream, which was shown to be increased in DPP4-deficient F344
rats (94). DPP4 cleaves eotaxin to eotaxin (3–74). However, there
was no significant correlation of eotaxin seen in patients with
T2DM or impaired glucose tolerance in the KORA cohort (95).
DPP4 as a Drug Target for the Treatment of T2DM
Deactivation of DPP4 Enzymatic Activity
DPP4 inhibitors
MajorDPP4 substrates are the so-called incretin hormones, which
are key regulators of post-prandial insulin release. DPP4 inhibi-
tion leads to greater bioavailability of these proteins and therefore
prolongs the half-life of insulin action. The majority of effects
seen upon DPP4-inhibitor treatment are ascribed to an increase
in GLP-1 levels. Because of this, DPP4 became a major target for
the treatment of T2DM. This section deals with the most recent
knowledge around DPP4 inhibitors, their mode of action – if
known – and the newest developments in the inhibition of DPP4
enzymatic activity. There are numerous modifications and poten-
tial optimizations of the five so far approved gliptins reported.
However, most of them are not in clinical trials yet and not much
is known about their advantage in a head to head comparison to
established gliptins. Therefore, we decided to focus on the most
recent data on approved gliptins in this review. The data are also
summarized in Table 1.
Dipeptidyl-peptidase 4 inhibitors lower DPP4 activity by
70–90%. They do not pass the blood–brain barrier and have
no direct effect on satiety or on altering gastric emptying
(8). The benefit for diabetes therapy clearly is their indiffer-
ence on bodyweight gain and the low risk of hypoglycemia.
There are five gliptins approved so far for clinical use, namely
sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin.
Three more gliptins, teneligliptin, anagliptin, and trelagliptin are
only approved in the Japanese and Korean market. Despite the
same mode of action, the different gliptins diverge in their phar-
macodynamic and pharmacokinetic properties, which might be
clinically relevant for some patients (9, 96). The peptide mimetic
compounds, vilda-, saxa, and teneligliptin, were identified by
replacement experiments of peptide-based substrates, whereas the
non-peptide mimetic compounds, sita, alo-, and linagliptin, were
derived from initially found inhibitors of random screenings. The
diverse chemical structures also explain the unique bindingmodes
of the inhibitors to DPP4 (10).
The six inhibitors have been classified into three classes
depending on their different binding modes in the DPP4 active
center (10). Class 1 contains vilda- and saxagliptin, which only
bind to the S1 and S2 subsites and form a covalent bond with
the nitrile group of their cyanopyrrolidine moiety and Ser630 of
DPP4. Saxagliptin has a fivefold higher activity in blocking DPP4
than vildagliptin. Group 2 contains alo- and linagliptin, which
also interact with the S10 subsite or even in case of linagliptin
with the S20 subsite. The uracil rings of both gliptins induce a
conformational change in the Tyr547 of the S10 subsite. Because
of the additional interaction of linagliptin with S20 subsite, it
has an eightfold higher activity than alogliptin. The third class
has the highest inhibitory function toward DPP4, because both
sita- and teneligliptin interact with the S2-extensive subsite of
the DPP4 active center, and an increasing number of interactions
seems to increase the potency of the gliptin (10). Teneligliptin,
which is only approved for T2DM treatment in the Japanese and
Korean market so far, also has a unique structure characterized
by a J-shape and an anchor-lock domain, which explains the
strong inhibitory function and the low IC50 value of this drug
[for review, see Ref. (97)]. The binding of the DPP4 S2-extensive
subsite of some inhibitors also guarantees a high specificity toward
DPP4 since other close-related peptidases like DPP8, DPP9, and
FAP lack this subsite. All DPP4 inhibitors have in common that
they build salt bridges with Glu-residues in the S2 subsite (10).
At least for sitagliptin, it is also known that it lowers the level
of free fatty acids (FFA) and thereby also comprises insulin-
sensitizing properties (98). Furthermore, sitagliptin was shown to
have potent anti-inflammatory properties by suppressing expres-
sion of pro-inflammatory genes in mouse and humans (98, 99).
In patients with renal impairment, which is a very common
complication of T2DM, sitagliptin is more suitable than sulfony-
lureas (100). Anagliptin, which is only approved since 2012 in the
Japanese market, seems to have serum lipid-lowering and anti-
atherogenic actions as well, which makes it unique among the
gliptins approved so far (101, 102). Anagliptin has an IC50 of
3.3 nM and its main excretion route is renal elimination (101,
103). However, since this gliptin is only on the market since 2012,
TABLE 1 | Summarized properties of gliptins.
Inhibitor Approved since Binding mode Kind of inhibition Route of excretion IC50 value Reference
Sitagliptin 2006 FDA S1, S2, and S2
extensive subsites
Competitive inhibition Mostly renal route 19 nM (10, 98–100)
Vildagliptin 2007 European
medicines agency
Only S1 and S2 subsite Substrate–enzyme blocker Mostly renal route 62 nM (10, 209)
Saxagliptin 2009 FDA Only S1 and S2 subsite Substrate–enzyme blocker Mostly renal route 50 nM (10, 209)
Linagliptin 2011 FDA S1, S2, and S10 subsites – Through biliary route 1 nM (10)
Alogliptin 2013 FDA S1, S2, and S10 subsites Competitive inhibition Mostly renal route 24 nM (8, 10)
Teneligliptin 2012 Japan S1, S2, and S2
extensive subsites
Very potent because of unique anchor-
lock domain and J-shape of molecule
Mostly renal route 0.37 nM (97)
2014 Korea
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comparative head-to-head trials and data on the long-term use
are missing at the moment. Shinjo and colleagues demonstrated
that anagliptin exerts anti-inflammatory effects on macrophages
and adipocytes in vitro and on inflamed mouse livers in vivo.
In this very recent study, anagliptin was more potent in its anti-
inflammatory actions than sitagliptin (104). To improve the qual-
ity of life of T2DM patients, development of novel agents now
is more and more focused on long-acting agents. There are two
more gliptins, which only have to be applied once weekly, namely
SYR-472 (trelagliptin) and MK-3102 (omarigliptin) (105, 106).
Trelagliptin is approved in Japan since 2015.
Although some authors claim that DPP4 inhibitors are only
beneficial in early stages of diabetes, this could be rebutted by
the work of Kumar and Gupta (107). They could show beneficial
effects of three gliptins (sita-, saxa-, and vildagliptin) in lower-
ing HbA1c also in patients with longstanding T2DM for more
than 10 years. Thus, DPP4 inhibition also plays an important role
irrespective of the duration of diabetes.
What has to be mentioned in respect of the beneficial roles
of DPP4 inhibitors is that more and more studies about their
beneficial pleiotropic effects are upcoming, which are also dis-
cussed in the following section of this reviewdealingwith different
organs. There are reports that gliptins themselves have effects
on lipid profile and blood pressure as well as on inflammatory
processes (108). In addition to the incretins, there are some DPP4
substrates, like SDF-1α, which might explain potential cardio-
protective effects, which are discussed for gliptins. However, car-
diovascular outcomes are still widely debated and controversially
evidenced. Ongoing long-term studies will further shed light on
the respective role of DPP4i beyond glucose homeostasis. Fur-
thermore, one has to keep in mind that also DPP4 has direct
effects independent of its enzymatic activity, like activation of
downstream signaling events upon receptor binding, which are
not well understood so far. Which role DPP4 inhibition plays
on T2D relevant organs/comorbidities will be the topic of the
following sections.
Alternative modes of DPP4 inhibition
Very recently, Pang and colleagues published a different strategy to
inhibit DPP4 activity. They used DPP4-targeted immune therapy
by vaccines in a C57BL/6J mouse model and were able to show
comparable effects like in treatments with gliptins regarding GLP-
1 plasma levels and post-prandial glucose excursion and insulin
sensitivity in HFD-fed mice. Furthermore, they observed no side
effects on immune cell activation by the DPP4 vaccine. An advan-
tage of this method is the long-lasting effect of the vaccine in the
mouse model, which could, if transferable to human patients, be
a convenient alternative to the daily intake of gliptins (109).
Further research in developing alternatives toward Gliptins
especially for long-acting medications would be an interesting
new approach to improve lifestyle of patients.
Incretin-Based Therapies: Comparing
DPP4i and GLP-1 Analogs
It is well accepted that incretin-based therapies are able to lower
blood glucose levels and are therefore a treatment option for
T2DM. There are mainly two approaches to target the incretin
system (1) via inhibiting the enzymatic action of DPP4 and
thereby upregulating GLP-1 levels physiologically and (2) via
increasing GLP-1 levels pharmacologically. While GLP-1 receptor
agonists (GLP-1-RA) directly target GLP-1, GLP-1-independent
effects are also possible with the use of DPP4 inhibitors (DPP4i).
These drugs might also affect the level of other DPP4 substrates
and might therefore have a more complex mode of action.
However, there have been a lot of attempts to compare the
effects ofGLP-1-RAversusDPP4i in clinical studies. The results of
these head-to-head comparisons are summarized inmany current
reviews (110–114). Most of these comparative studies agree that
GLP-1 analogs are more effective in respect of glycemic con-
trol. Both incretin-based therapies are equally potent in lowering
blood pressure and total cholesterol (110). Furthermore, both have
the advantage of low incidence of hypoglycemia (110, 111). The
results for body-weight lowering effects of DPP4i are heteroge-
neous throughout the studies (113), whereas beneficial effects
on body-weight are well accepted for GLP-1-RA (110–112, 114).
Therefore, some authors tend to prefer GLP-1-RA over the use of
DPP4i (112). However, one should be aware of the fact, that GLP-
1-RA have a higher incidence of gastrointestinal adverse events
like nausea (110, 112, 114), which might be disadvantageous for
elderly people who may be more prone to these side effects (114).
Furthermore, there are reports that DPP4i might also have car-
dioprotective effects (113), which will also shortly be discussed in
section “Effect of DPP4 Inhibition on the Cardiovascular System”
of this review. Despite the clear beneficial effects of incretin-based
therapies, there are also concerns reported in respect of the risk for
long-term complications like pancreatitis (115). These potential
risks might, however, outweigh the benefits. These controversial
discussions are well summarized by the reviews of Nauck and
Butler (115, 116).
To really assess whichmedication is of more importance always
depends on the special patient characteristic.
Impact of DPP4 on T2DM-Relevant Organs
and Associated Comorbidities
Dipeptidyl-peptidase 4 inhibitors exert glucose regulatory actions
by prolonging the effects of GLP-1 and GIP, ultimately increas-
ing glucose-mediated insulin secretion and suppressing glucagon
secretion (117). Beside the glucose-lowering properties of DPP4
inhibitors, emerging evidence suggests that incretin-based ther-
apies may also have a positive impact on inflammation, cardio-
vascular and hepatic health, sleep, and the central nervous system
(118). However, the underlying mechanisms of these effects can-
not be fully explained by lower blood glucose levels or increased
GLP-1 bioavailability or signaling, and has to be further eluci-
dated. Thus, the next section is focused on the role of DPP4 action
in T2DM-relevant organs and associated comorbidities.
Adipose Tissue
Adipose tissue is the primary storage organ for excess energy.
While the role of adipose tissue as a central source of energy
has been recognized for centuries, in the past decade, it has
become increasingly clear that adipose tissue also displays char-
acteristics of an endocrine organ releasing a number of adipose
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tissue-specific factors, known as adipokines. During the progres-
sion of obesity, the ability of adipocytes to function as endocrine
cells and to secrete multiple biologically active proteins is affected
(119). Thus, adipose tissue has been shown to be a central driver of
T2DM progression, establishing and maintaining a chronic state
of low-level inflammation (120).
DPP4 Expression and Release Within Adipose Tissue
Recently, we showed that DPP4 is highly expressed in human
primary adipocytes (4). Furthermore, DPP4 expression in adipose
tissue is increased in obese compared to lean individuals in both
subcutaneous and visceral adipose tissue (4, 5). Interestingly,
visceral fat of obese patients exhibits the highest DPP4 level.
According to the increased expression, we could identify sDPP4
as a novel adipokine released from primary human adipocytes.
In vitro, the DPP4 release increased substantially during fat cell
differentiation, and comparison with preadipocytes and adipose
tissue, macrophages showed that adipocytes most likely represent
the major source of DPP4 released from the intact organ to the
circulation. Furthermore, the release of sDPP4 was elevated in
adipose tissue explants of obese patients compared to lean controls
and correlates with various classical markers of themetabolic syn-
drome, namely BMI, waist circumference, plasma triglycerides,
and HOMA as an index of IR, as well as with fat cell volume and
the adipokine leptin (4, 5).
How DPP4 expression affects adipocyte homeostasis can only
be speculated. DPP4 might be involved in adipose tissue lipolysis.
DPP4 recruits ADA, a monomeric enzyme catalyzing deamina-
tion of adenosine to inosine and ammonia (121, 122). It has been
shown that DPP4-bound ADA has a 1000-fold greater activity
than free ADA (123), which in turn may modulate the well-
established antilipolytic effects of adenosine. Moreover, DPP4
is a strong inhibitor of the antilipolytic activity of NPY (76),
which is one of the best peptide substrates of the enzyme (89). In
this regard, Rosmaninho-Salgadoa and colleagues demonstrated
that DPP4 stimulates lipid accumulation and PPAR-γ expression
through cleavage of NPY suggesting that sDPP4 might stimulate
adipocyte differentiation (77). However, it is noteworthy that the
authors of this study were using tremendously high and non-
physiological concentrations of sDPP4. On the contrary, a recent
published study showed that DPP4 expressionwas strongly upreg-
ulated during adipocyte dedifferentiation in vitro. Hence, the
authors concluded that DPP4 might be a major component in
adipose tissue remodeling and cell plasticity (124). Nevertheless,
enhanced abundance of DPP4 within adipose tissue of obese
subjects may be involved in adipose tissue remodeling and sub-
stantially augments the lipolytic activity of enlarged adipocytes
(57, 58).
Moreover, dendritic cells and macrophages resident in visceral
adipose depots exhibit an increased DPP4 expression in response
to inflammation or in the obese state (28). Since it is known that
DPP4 exerts immunomodulating properties, Zhong et al. showed
that membrane-bound DPP4 is co-localized with membrane-
bound ADA on human dendritic cells resulting in an increased T-
cell proliferation (28). Thus, it can be speculated that DPP4 might
also play an important role in the chronic low-grade inflammation
taking place in obesity and T2DM.
Adipose Tissue as Relevant Source of Circulating
DPP4
Serum levels of sDPP4 are altered in many pathophysiologic
conditions, including different types of cancer, allergic asthma,
or hepatitis C (7). Our group was the first analyzing circulat-
ing sDPP4 in the context of obesity and the metabolic syn-
drome. DPP4 serum levels of morbidly obese men are elevated
compared with lean controls and significantly correlated with
BMI, the size of adipocytes in subcutaneous and visceral fat,
and the adipocyte hormones adiponectin (negatively) and leptin.
These data suggest that sDPP4 is related not only to increased
body weight but also to other important parameters of adipose
tissue physiology. In addition, sDPP4 release and serum con-
centration can be reversed to normal levels by surgery-induced
weight loss (4). Thus, in obesity, both circulating levels of sDPP4
and sDPP4 release by adipose tissue are increased and correlate
strongly with the metabolic syndrome but can be reduced to
control levels by substantial weight loss. Thus, indicating that
enlargement of visceral adipocytes in obesity may substantially
contribute to the augmented level of circulating sDPP4 in obese
patients.
Endocrine Effects of Soluble DPP4
Although there is clear evidence that increased circulating levels of
sDPP4 are associated with hallmarks of obesity and type diabetes,
such as whole-body IR, elevated BMI, and adipocyte hypertrophy,
there are only few studies investigating the endocrine effects of
sDPP4. We were the first showing that DPP4 consistently impairs
insulin signaling at the level of Akt in primary human adipocytes
(4). Enzymatic activity of sDPP4 appears to be involved in this
process; however, since this work was done in vitro, it is most
unlikely that the sDPP4-induced impairment of insulin action
is due to an increased bioavailability of any DPP4 substrate. It
might rather be that DPP4 inhibitors may also affect the binding
properties of sDPP4 to its receptors, namely M6P/IGFII receptor
(38) or PAR2 (39). For the latter, it is not only known that PAR2
signaling induces IR in adipocytes (125), but PAR2 might also be
a substantial contributor to inflammatory andmetabolic dysfunc-
tion (126). Although there is a hint that circulating sDPP4 itself
might affect adipose tissue function, the exact mechanism has to
be further investigated.
Impact of DPP4 Inhibition on Adipose Tissue
To further investigate the role of DPP4 in adipose tissue, several
studies with DPP4 inhibitors were conducted. Interestingly, the
administration of the DPP4-inhibitior des-fluoro-sitagliptin ame-
liorates linoleic acid-induced adipose tissue hypertrophy in β-cell-
specific glucokinase haploinsufficient mice, a model of non-obese
T2DM (127). Moreover, des-fluoro-sitagliptin protects against
linoleic acid-induced adipose tissue inflammation illustrated by
CD8+ T-cell infiltration. Due to the loss of GLP-1 receptors in
adipose tissue, the authors exclude the involvement of GLP-1 and
claim that the observed effects are due to the huge variety of
DPP4 substrates. Thus, DPP4 inhibition might have pleiotropic
effects in adipose tissue. A similar outcome has been observed
in C57BL/6 mice fed a HFD. After linagliptin treatment, a sig-
nificantly lower expression of the macrophage marker F4/80 was
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found compared with vehicle treatment. In line with these data,
the authors demonstrated an increased insulin sensitivity after
linagliptin treatment suggesting that DPP4 and adipose tissue
inflammation play a pivotal role in the induction of IR. In 3T3-
L1 cells, a murine predipocyte cell line, Rosmaninho-Salgado
et al. demonstrated that the DPP4-inhibitor vildagliptin reduces
lipid accumulation by inhibiting adipogenesis, without affecting
lipolysis through NPY cleavage and subsequent NPY Y2 receptor
activation (77).
With the recognition that adult humans also have BAT, an
organ with substantial capacity to dissipate energy, BAT gained
considerable interest as a novel target to treat or prevent obesity
and its associated diseases. In 2013, the group around Shimasaki
was the first reporting that des-fluoro-sitagliptin attenuated body
adiposity, without affecting food intake, in C57BL/6 mice with
diet-induced obesity (128). The increase in energy expenditure
could be explained by enhanced levels of PPAR-α, PGC-1, and
uncoupling protein-1 (UCP-1) in BAT as well as elevated lev-
els of proopiomelanocortin in the hypothalamus. The beneficial
effects of des-fluoro-sitagliptin on energy expenditure could only
partly be ascribed to increased GLP-1 levels and have to be
further validated. Shortly afterward, Fukuda-Tsuru et al. could
confirm these data in the same animal model by administra-
tion of teneligliptin (129). Moreover, in this study, teneligliptin
also reduces fat mass and suppresses HFD-induced adipocyte
hypertrophy.
Collectively, there is clear evidence that DPP4 expression
and release by adipose tissue play a key role in obesity and
T2DM-associated processes, such as inflammation, adipocyte
hypertrophy, and IR. However, the underlying mechanism of
these beneficial effects is not fully understood and remains unclear
in most of the publications.
Pancreatic Islets
β-cells play a central role in the etiology of T2DM.Due to failure of
β-cell sensitivity to glucose and loss of β-cell mass, insulin secre-
tion of these cells is not sufficient to counter balance IR, finally
leading to T2DM. Although DPP4 inhibitors are now widely used
for glycemic control, many debates are ongoing about their exact
mode of action and their beneficial effects on pancreatic β cells.
Regulation of DPP4 Expression Within Pancreatic
Islets
Interestingly, within the pancreatic islets, DPP4 localization dif-
fers between species. Islets of rodents showed a near-exclusive
expression of DPP4 in β cells, with little expression in α-cells. In
contrast, human and pig islets express DPP4 almost exclusively
in α cells (130, 131). The species difference in the localization of
DPP4 expression, and the possible physiological consequence of
that difference, is unclear. Moreover, in a recent published study,
it has been demonstrated that DPP4 activity was detectable in
the conditioned medium of human islets suggesting that DPP4
is released from human islets as well (132). Under pathological
conditions, islets of obese mice chronically fed a HFD that exhibit
an increased DPP4 activity. The contrary was found in human
islets from type 2 diabetic donors, showing a decreased DPP4
activity (131).
Impact of DPP4 Inhibition on Pancreatic Islets
Accumulating in vitro and pre-clinical data show that DPP4 inhi-
bition has beneficial effects on T2DM induced β-cell dysfunction
and apoptosis. Omar and colleagues demonstrated that DPP4
is not only present and active in mouse and human islets, but
inhibition of islet DPP4 activity also has a direct stimulatory
effect on insulin secretion, which is GLP-1 dependent (131). The
same effect could be observedwith a 2-week des-fluoro-sitagliptin
treatment leading to increased insulin exocytosis by β cells from
db/db diabetic mice (133). Furthermore, it could be shown that
DPP4 inhibition is clearly associated with significantly increased
β-cell mass and function in several models of T2DM (134–136).
These beneficial effects were associated with the transcriptional
activation of anti-apoptotic and pro-survival genes, as well as the
suppression of pro-apoptotic genes in β cells (137). Additionally,
Shah and collaborators showed that theDPP4-inhibitor linagliptin
protects isolated human islets from gluco-, lipo-, and cytokine-
toxicity (132). Accordingly, Akarte et al. reported anti-oxidative
properties of vildagliptin shown by a dose-dependent decrease
in nitric oxide concentrations in both serum and pancreatic
homogenates of vildagliptin-treated diabetic rats (138).
Beside these pre-clinical and in vitro studies, only few are
known about the beneficial effect of DPP4 inhibitors on β cells in
human. In the short-term, 12-weeks vildagliptin treatment leads
to a small increase in the capacity for insulin secretion (139).
Treatment with vildagliptin over a longer period of time could
also confirm an increased β-cell function in humans as a result
of improved sensitivity of β cells to glucose (140, 141). However,
this effect was not maintained after washout period, indicating
that this increased capacity was not a disease modifying effect on
beta cellmass and/or function. In the SAVOR-TIMI 53 trial, which
was originally performed to assess the cardiovascular safety of
saxagliptin, Leibowitz and colleagues recently reported that DPP4
inhibition may attenuate the progression of diabetes (142). This
was evidenced by a decreased requirement for intensification of
treatment associated with better preservation of glycemic control,
as well as better sustained β-cell function as reflected in the fasting
HOMA-2β during the 2-year follow-up period.
The exact mechanism how DPP4 inhibitors augment insulin
secretion and increase β-cell mass in vitro and in vivo is still not
fully understood, since not all these effects could be explained by
elevatedGLP-1 level or improved glycemic control associatedwith
less glucotoxicity.
Liver
Non-alcoholic fatty liver disease (NAFLD) describes a disorder
with excessive deposition of fat within the liver with increasing
prevalence in parallel to obesity and diabetes, which are major
risk factors for NAFLD (143). Indeed, NAFLD is now the most
common cause of chronic liver disease (144) and is present in
one-quarter to one-half of diabetes patients (145). In the obese
state, elevated triglyceride degradation in adipose tissue causes
an increased hepatic uptake of fatty acids leading to fat accu-
mulation within the tissue. Furthermore, reactive oxygen species
(ROS), produced during lipid oxidation, are assumed to induce
hepatocyte death and inflammatory reactions. Liver cirrhosis can
be defined as the end stage of chronic liver diseases and is caused
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by progressive fibrosis. This process is characterized by excessive
accumulation of ECM and activated hepatic stellate cells (146,
147) that ultimately results in nodular regeneration with loss of
function (148).
Regulation of DPP4 Expression in the Liver
Although DPP4 exhibits a widespread organ distribution, the
liver is one of the organs that highly expresses DPP4 (149). In
the healthy human liver, intense staining for DPP4 was found in
hepatic acinar zones 2 and 3, but not in zone 1. This heterogeneous
lobular distribution suggests that DPP4 might be involved in
the regulation of hepatic metabolism (150). Furthermore, mRNA
expression levels of DPP4 were significantly increased in NAFLD
livers compared to that in control livers (151). In accordance to
that, DPP4 expression levels of NAFLD patients were negatively
correlated with HOMA-IR and BMI, and positively correlated
with total cholesterol levels, but not with ALT, lactate dehydro-
genase (LDH), or triglyceride levels. Moreover, under conditions
of high glucose, DPP4 expression was increased in HepG2 cells.
However, other nutritional conditions, such as high insulin or the
presence of fatty acids and cholesterol, did not affect DPP4 expres-
sion in these cells. Thus, the authors claim that enhanced DPP4
expression in NAFLD liver may rather be associated with IR than
triglyceride accumulation and may promote the progression of
liver disease via subsequent deteriorations in glucose metabolism.
How increased DPP4 expression might affect liver function is still
unknown. There are only a fewhints thatDPP4might play a role in
fibronectin-mediated interaction of hepatocytes with extracellular
matrix (2, 36, 152). Beside DPP4 expression, there is only indirect
evidence that hepatocytes also release DPP4 to the circulation,
which will be further discussed in the next section.
Serum Level of DPP4 in Liver Disease
As previously discussed, hepatic DPP4 mRNA expression level in
the livers is significantly higher in patients withNAFLD compared
to healthy subjects (151). This upregulation of hepatic DPP4
expression is thought to be responsible for elevated DPP4 serum
level in patients with liver disease (153–155). In line with this
observation, serum DPP4 activity can be correlated with hep-
atic steatosis and NAFLD grading (156). Similarly, in patients
with NAFLD, DPP4 activity in serum correlates with markers of
liver damage, such as serum gamma-glutamyltranspeptidase and
ALT levels, but do not correlate with fasting blood glucose levels
and HbA1c values (156, 157). Thus, hepatic DPP4 expression in
NAFLD may be directly associated with increased DPP4 serum
level and may be involved in hepatic lipogenesis and liver injury.
Impact of DPP4 Inhibition on Liver Function
Since DPP4 inhibitors are widely used in clinical practice, this
drug was also investigated as a potential new therapeutic strategy
against the development of liver fibrosis and steatosis. Kaji and
collaborators demonstrated that sitagliptinmarkedly inhibits liver
fibrosis development in rats via suppression of hepatic stellate
cell proliferation and collagen synthesis (158). These suppressive
effects were associated with dephosphorylation of ERK1/2, p38,
and Smad2/3 in the hepatic stellate cells. Additionally, hepatic
steatosis could be prevented in several different animal models
by DPP4 inhibition (127, 159, 160). Shirakawa and colleagues
studied the effects of sitagliptin in glucokinase diabetic mice
with diet-induced hepatic steatosis (127). Here, sitagliptin pre-
vented fatty liver in both wild-type and glucokinasemice paral-
leled by decreased expression of sterol regulatory element-binding
protein-1c, stearoyl-CoA desaturase-1, and fatty acid synthase,
and increased expression of peroxisome proliferator-activated
receptor-α in the liver. Furthermore, in a mouse model of non-
alcoholic steatohepatitis, further studies indicated that linagliptin
improves insulin sensitivity and hepatic steatosis in mice with
diet-induced obesity (161) and ameliorates liver inflammation
(162). The underlying mechanism of these beneficial effects has
been further investigated by Ohyama et al. in ob/ob mice (163).
The novel DPP4-inhibitor MK-0626 attenuates hepatic steatosis
by enhancing AMPK activity, inhibiting hepatic lipogenic gene
expression, increasing triglyceride secretion from liver, and ele-
vating serum adiponectin levels.
Clinical data are very limited; however, several non-
randomized trials conducted in small groups of diabetic
patients demonstrated that DPP4 inhibitors improved the levels
of liver transaminases and liver fat (164–166). Accordingly,
Iwasaki et al. found a decrease in ballooning and non-alcoholic
steatohepatitis scores in post-treatment liver biopsies (165, 166).
Recently, in a comprehensive retrospective review of 459 type
2 diabetic patients, treated with DPP4-inhibitors, it was shown
that DPP4 inhibitors improved the abnormality of the liver
transaminases AST and ALT independent of HbA1c and body
weight (167). Again in the majority of publications, the authors
postulate that these beneficial actions were mediated through
potentiation of direct GLP-1 actions on hepatocytes; however,
it seems unlikely that hepatocytes express the canonical GLP-1
receptor (168).
In conclusion, accumulating studies indicate that DPP4
inhibitors are clinically useful for patients with T2DM accom-
panied by liver dysfunction based on fatty liver, and that DPP4
inhibition affects liver function regardless of diabetic status and
obesity.
Cardiovascular System
Cardiovascular complications (CVD) are common in patients
with T2DM and a major cause of mortality (169). Atheroscle-
rosis is the dominant cause of CVD and usually develops many
years before any clinical symptoms are manifested. The underly-
ing pathogenesis of atherosclerosis involves an imbalanced lipid
metabolism and a maladaptive immune response entailing a
chronic low-grade inflammation of the arterial wall. Endothe-
lial cells and intimal smooth muscle cells represent the major
cell types of the artery wall preserving vessel wall homeosta-
sis. Together with leukocytes, they are the major players in the
development of this disease. Beside atherosclerosis, T2DM also
exacerbates heart failure associated with diastolic heart failure and
coronary microangiopathy (170–172).
Regulation of DPP4 Expression and Release
in Vascular Cells
Dipeptidyl-peptidase 4 is expressed in both microvascular
endothelial cells of different human tissues, such as liver, spleen,
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lung, brain, heart (170, 172), and in human vascular smooth
muscle cells (3). Under conditions of high glucose, DPP4 expres-
sion and activity were increased in human glomerular endothelial
cells (173). Additionally, in STZ-induced diabetic rats, activity of
membrane-bound DPP4 was increased, thereby reducing cardiac
SDF-1 concentrations and causing impaired angiogenesis (174).
Also hypoxia has been shown to regulate DPP4 expression in
vascular cells. Regarding endothelial cells, there are conflicting
data on the influence of hypoxia on DPP4 expression. In human
microvascular endothelial cells as well as human umbilical vein
endothelial cells, Eltzschig and colleagues showed that hypoxia
increased DPP4 mRNA and protein level (175), whereas another
study by Shigeta et al. observed a decreased protein level of DPP4
under hypoxic conditions in the same cells (174). However, in
human vascular smooth muscle cells, we observed an increased
DPP4 expression in response to hypoxia (3). In this particular
study, we could also show that DPP4 is released from human
vascular smooth muscle cells. However, only very little is known
about the physiological role of themembrane-boundDPP4within
the vasculature. There is only one study showing that DPP4
forms a complex with ADA capable of degrading extracellular
adenosine to inosine in endothelial cells. Increased inosine levels
in turn are known to induce vasoconstriction due to mast cell
degranulation (176).
Effect of DPP4 Inhibition on the
Cardiovascular System
In several in vitro and pre-clinical studies, DPP4 inhibitors have
been shown to exert important protective effects on the cardio-
vascular system. In this regard, it has been shown that DPP4
inhibitors decrease myocardial infarct size, stabilize the cardiac
electrophysiological state during myocardial ischemia, reduce
ischemia/reperfusion injury, and prevent left ventricular remod-
eling following MI (177, 178). Additionally, DPP4 inhibitors also
exert vascular protective properties, including anti-inflammatory
and anti-atherosclerotic effects and the ability to induce vascular
relaxation (179, 180). To confirm cardiovascular safety or even
protection of DPP4 inhibitors in humans, several cardiovascular
outcome studies were conducted. However, several clinical trials,
namely SAVOR-TIMI 53, EXAMINE, or VIVIDD in patients
with established cardiovascular disease failed to confirm a cardio-
protective effect (181–183). Even an increased cardiovascular risk
for DPP4 inhibitors was discussed, since in the SAVOR-TIMI 53
trial, a significant increased hospitalization due to heart failure in
the saxagliptin-treated group was observed. However, in the most
recent published outcome study TECOS, the authors could show
that among patients with T2DM and established cardiovascular
disease, sitagliptin did not appear to increase the risk of major
adverse cardiovascular events, hospitalization for heart failure, or
other adverse events (184). As sDPP4 is an adipokine upregulated
in obesity and T2DM that triggers IR and metabolic complica-
tions (4, 5), it might be speculated that the beneficial effects of
DPP4 inhibitors would be higher in those early phases of the
metabolic disorders previous to the development of established
cardiovascular disease.
However, whether these beneficial effects observed in pre-
clinical settings are due to increased levels of different DPP4
substrates or inhibition of direct effects of DPP4 remains unclear
and will be assessed in more detail in the following section.
DPP4 Substrates: GLP-1 Dependent Effects of
DPP4 Inhibitors
Since several studies have identified a role for GLP-1 recep-
tor (GLP-1R) signaling in DPP4-dependent cardioprotection,
it is suggested that GLP-1 itself has favorable cardiovascular
effects. Indeed, mRNA transcripts of the GLP-1R have been
detected in the heart of rodents (185, 186) and humans (187).
Furthermore, GLP-1R has also been localized to mouse aortic
smooth muscle and endothelial cells, as well as monocytes and
macrophages (188).
Regarding MI and heart failure, pre-clinical studies have
demonstrated that DPP4-deficient rats subjected to 45min of
ischemia with 2 h or reperfusion exhibited cardioprotection illus-
trated by reduced infarct size, improved cardiac performance, and
reduced levels of BNP compared to control rats (189). These ben-
eficial effects could be partially reversed by co-administration of
the GLP-1R antagonist exendin (9–39). Accordingly, administra-
tion of exendin (9–39) reversed the sitagliptin-induced improve-
ment in ventricular function in Sprague Dawley rats with tran-
sient cardiac ischemia (190). Additionally, in a rat model of
chronic heart failure, GLP-1 analogs were able to improve cardiac
function and morphology, with a concomitant amelioration of
hyperglycemia and hyperinsulinemia (191).
Regarding the vascular system, continuous infusion of the
GLP-1 analog exendin-4 reduced monocyte adhesion to aortic
endothelial cells, associated with a reduction in atherosclerotic
lesion size in non-diabetic C57BL/6 and ApoE /  mice. Further-
more, treatment for 1 h with exendin-4 reduced the expression of
the pro-inflammatory cytokines, TNFα and MCP-1, in response
to lipopolysaccharide (LPS) (188). In addition, exendin-4 stim-
ulates proliferation of human coronary artery endothelial cells
through endothelial nitric oxide synthase (eNOS)-, protein kinase
A (PKA)-, and PI3K/Akt-dependent pathways (192, 193). Accord-
ingly, in humans, preliminary data confirm the ability of GLP-1 to
protect from high glucose-induced endothelial dysfunction in the
post-meal phase (194). In a model of vascular injury, it has been
shown that continuous infusion of exendin-4 reduces neointimal
formation at 4weeks after injury without altering body weight or
various metabolic parameters (195). From in vitro studies, Goto
et al. suggest that this effect wasmediated by the ability ofGLP-1 to
suppress platelet-derived growth factor (PDGF)-induced prolifer-
ation of vascular smoothmuscle cells. In contrast, in a pre-clinical
study, combining HFD and STZ treatment in ApoE /  failed to
detect evidence for GLP-1R-dependent reduction of lesion size in
the thoracic or abdominal aorta (168). The authors discuss that
the duration of treatment, the dose of the GLP-1 agonist, or the
age of mice might be responsible for the lack of anti-atherogenic
activity in this study.
However, in patientswith heart failure, pilot studies also suggest
cardioprotection by GLP-1 infusion (196, 197). Accordingly, a
large retrospective analysis indicates that patients treated with the
GLP-1 analog exenatide had a significant 20% reduction of CVD
events compared with patients on other glucose-lowering agents
(198). Nevertheless, studies showing cardiovascular protective
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FIGURE 2 | Schematic overview of the impact of soluble DPP4 and
DPP4 inhibitors on T2DM-relevant organs/tissues. In the upper panel,
direct effects of soluble DPP4 (in red) on different organs/tissues are
presented (gray boxes). The lower panel shows known effects of DPP4
inhibitors (in green) in these particular organs/tissues (gray boxes). SMC,
smooth muscle cells.
effects of GLP-1 were carried out using either native GLP-1 or
recombinant GLP-1 analogs at high concentrations or in a way
that induced supraphysiological GLP-1 signaling. Considering
that DPP4 inhibition restores GLP-1 signaling within the phys-
iological range, beneficial effects of DPP4 inhibitors might be
different to those of GLP-1 analogs.
DPP4 Substrates: SDF-1- and BNP-Dependent
Effects of DPP4 Inhibitors
But beside GLP-1, there are further substrates of DPP4, which
might play a role in the favorable cardiovascular effects of DPP4
inhibitors. Two of the most promising candidates are SDF-1α
and brain natriuretic peptide (BNP). As already mentioned in
section “Stromal Cell-Derived Factor-1α/CXCL12,” SDF-1 is a
chemokine promoting stem-cell homing of EPCs by binding to
its receptor C–X–C motif chemokine receptor type 4 (CXCR4).
EPCs are derived from the bone marrow and are known to pro-
mote vascular repair and neoangiogenesis. When vascular dam-
age occurs, local growth factors and cytokines signal the bone
marrow to release EPC targeted to the injured sites. EPC then
differentiate into mature endothelial cells and assist in the recon-
struction of the vasculature (199). In mice, genetic deletion or
pharmacologic inhibition of DPP4 is able to increase the homing
of CXCR4+ EPC at sites of myocardial damage, resulting in a
reduced cardiac remodeling and improved heart function and
survival (200). In a human study, Fadini et al. demonstrated that
type 2 diabetic patients receiving a 4-week course of therapy with
the DPP4-inhibitor sitagliptin show increased SDF-1α plasma
concentrations and circulating EPC levels (199). Additionally,
SDF-1 engineered to be resistant to DPP4 cleavage, and delivered
by nanofibers, improves blood flow in amodel of peripheral artery
disease (201). Collectively, these studies implicate a rationale to
use DPP4 inhibitors for vascular repair through stimulation of
EPC and neovascularization.
Brain natriuretic peptide, another substrate of DPP4, plays an
important role in regulating body fluid homeostasis and vascular
tone through binding and subsequent activation of the cGMP-
coupled natriuretic peptide receptor type A (NPR-A) (202).
BNP is secreted predominantly by ventricular cardiomyocytes in
response to increased wall stress. Thus, elevated BNP is a sensitive
marker of heart failure and appears to play a role in cardiac
remodeling and healing after acute MI (203–205). DPP4 cleavage
of the physiologically active BNP (1–32) to BNP (3–32) effectively
lowers plasma cGMP levels, reduces diuresis and natriuresis, and
inhibits vasodilatation (83, 202).
Endocrine Effects of Soluble DPP4 on Cardiovascular
Homeostasis
Although it is well established that serum levels of sDPP4 are
altered in several pathological conditions and that sDPP4 is
released from vascular cells, only a minor part of research has
focused on potential endocrine effects of this proteolytic enzyme.
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Considering that DPP4 is discussed in immunomodulation,
it might be speculated that the inhibition of DPP4 modulates
responses occurring within early or late atherosclerotic lesions.
In low-density lipoprotein receptor-deficient (LDLR / ) mice,
Shah et al. could demonstrate that exogenously injected DPP4
increases monocyte migration in vivo (180). Although these
pro-migratory properties of DPP4 could be completely inhib-
ited by sitagliptin, the underlying mechanism of these effects
remains unclear. Moreover, the combined treatment of sDPP4
and LPS leads to increased expression and secretion of the pro-
inflammatory cytokines, TNFα and IL-6. This upregulation was
achieved by elevated levels of ERK, c-Fos, NF-κB p65, NF-κB
p50, and CUX1, all factors known to bind to the promotor
of TNFα and IL-6 (180). In accordance to that, Ikushima and
collaborators observed that sDPP4 binds to the M6P/IGF-IIR
resulting in enhanced transendothelial T cell migration (206). In
a further study, sDPP4 binding to M6P/IGF-IIR leads to elevated
ROS levels in HUVECs. In both studies, binding of DPP4 to
this particular receptor was completely prevented by a DPP4
inhibitor (207).
In human vascular smooth muscle cells, we could show that
sDPP4 activates theMAPKandNF-κB signaling cascade resulting
in pro-atherogenic changes in human vascular smooth muscle
cells illustrated by an increased proliferation, the induction of
iNOS and elevated expression, and secretion of pro-inflammatory
cytokines (39). Additionally, we observed that all these detrimen-
tal effects of sDPP4 were PAR2 mediated, since both a PAR2
antagonist and PAR2 silencing completely prevented the sDPP4-
induced effects. In collaborationwith the group of Sánchez-Ferrer,
we further showed that sDPP4 exhibits direct effects on vascu-
lar function illustrated by vascular reactivity of murine mesen-
teric arteries (208). sDPP4 impaired the endothelium-dependent
relaxation to acetylcholine in a concentration-dependent man-
ner by up to 75%, without modifying endothelium-independent
relaxation to sodium nitroprusside. Again, enzymatic activity
of DPP4 appears to be involved in this process. Similarly,
the cyclooxygenase inhibitor indomethacin and the thrombox-
ane A2 receptor antagonist SQ29548 abrogated the impairing
action of DPP4. These data suggest that DPP4 directly impairs
endothelium-dependent relaxation through a mechanism that
involves cyclooxygenase activation, and likely the release of a vaso-
constrictor prostanoid. Since sDPP4 has been reported not only
to contribute to monocyte migration and macrophage-mediated
inflammatory reactions but also stimulates the proliferation of
human coronary artery smooth muscle cells as well as impairs
endothelium-dependent vasorelaxation, it might be speculated
that sDPP4 itself acts as a risk factor for atherosclerosis.
Collectively, this section emphasizes that both membrane-
bound and sDPP4 and its inhibition are not only playing an impor-
tant role in glucose homeostasis but also in several other processes
and organs involved in the pathogenesis of T2DM (Figure 2). This
supports the notion that DPP4 exhibits pleiotropic properties that
are not fully understood so far and have to be further elucidated
in the future.
Conclusion
Dipeptidyl-peptidase 4, originally identified as an enzyme nearly
50 years ago, has now been recognized to exert pleiotropic func-
tions with substantial impact for a variety of diseases. The com-
plexity of DPP4 action stems from (i) a long list of substrates
cleaved by the enzyme including hormones, growth factors, and
cytokines, (ii) an additional function of this protein being a bind-
ing partner at the surface of different cells, specifically immune
cells, and (iii) the recent discovery that DPP4 is an adipokine with
different endocrine functions. Thus, an integrated view on this
molecule is required to more precisely understand its impact for
metabolic diseases like type 2 diabetes. For this disease, DPP4
inhibition has gained substantial interest, mostly related to the
DPP4 substrate, GLP-1. As shown here, other substrates like SDF-
1 and BNP should also be taken into account and may help to
better understand the therapeutic potential of DPP4 inhibitors.
In this context, the direct effects of DPP4 inhibitors require to
be assessed in more detail, and several aspects like the cardio-
protective function of DPP4 inhibition remains controversial.
Finally, soluble DPP4 is emerging as a new research line, putting
thismolecule to the list of adipo-cytokines with pro-inflammatory
and proliferative function. Combining the accumulated knowl-
edge on DPP4 will lead to an improved understanding of its
impact for health and disease.
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